All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Acadia Pharmaceuticals Inc., of San Diego, reported that net third-quarter sales of Nuplazid, (pimavanserin), to treat hallucinations and delusions associated with Parkinson's disease psychosis, were $58.3 million, an increase of 64 percent, as compared to $35.6 million reported for the three months ended Sept. 30, 2017.